# Lihua E Budde

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7881900/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 42<br>papers | 2,684<br>citations | 430874<br>18<br>h-index | 315739<br>38<br>g-index |
| 42<br>all docs | 42<br>docs citations | 42<br>times ranked | 3713<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295. | 8.2 | 498 |
| 2 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289. | 4.9 | 393 |
| 3 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241. | 4.9 | 284 |
| 4 | Phase 1 studies of central memoryâ€“derived CD19 CAR Tâ€“cell therapy following autologous HSCT in patients with B-cell NHL. Blood, 2016, 127, 2980-2990. | 1.4 | 264 |
| 5 | Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. PLoS ONE, 2013, 8, e82742. | 2.5 | 167 |
| 6 | Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2022, 40, 481-491. | 1.6 | 160 |
| 7 | Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 24-31. | 1.6 | 152 |
| 8 | Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 387-405. | 4.9 | 124 |
| 9 | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncology, The, 2022, 23, 1055-1065. | 10.7 | 119 |
| 10 | Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. , 2017, 5, 26. | | 72 |
| 11 | CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063. | 5.2 | 62 |
| 12 | CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research, 2015, 21, 2993-3002. | 7.0 | 52 |
| 13 | Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 514-520. | 2.0 | 31 |
| 14 | Preserved Activity of CD20-Specific Chimeric Antigen Receptorâ€“Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research, 2016, 4, 509-519. | 3.4 | 27 |
| 15 | Comparison of naÃ¯ve and central memory derived CD8<sup>+</sup>effector cell engraftment fitness and function following adoptive transfer. OncoImmunology, 2016, 5, e1072671. | 4.6 | 25 |
| 16 | The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88. | 3.4 | 24 |
| 17 | Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. Journal of Immunotherapy, 2018, 41, 19-31. | 2.4 | 23 |
| 18 | Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood, 2019, 134, 760-760. | 1.4 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biology of Blood and Marrow Transplantation, 2017, 23, 1861-1869. | 2.0 | 19 |
| 20 | ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Advances, 2020, 4, 2548-2555. | 5.2 | 19 |
| 21 | CD19 CAR-T therapy and sepsis: dancing with the devil. Blood, 2018, 131, 7-8. | 1.4 | 17 |
| 22 | Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood, 2022, 140, 2697-2708. | 1.4 | 15 |
| 23 | Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 104-104. | 1.4 | 14 |
| 24 | Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2021, 138, 133-133. | 1.4 | 13 |
| 25 | Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539. | 1.8 | 12 |
| 26 | Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncology, 2021, 17, 3549-3560. | 2.4 | 10 |
| 27 | CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075. | 1.4 | 10 |
| 28 | Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. Blood, 2019, 134, 1285-1285. | 1.4 | 9 |
| 29 | Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 3991-3991. | 1.4 | 9 |
| 30 | Bendamustine with rituximab, etoposide and carboplatin (T(R)<scp>EC</scp>) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. British Journal of Haematology, 2018, 183, 601-607. | 2.5 | 7 |
| 31 | Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). Blood, 2019, 134, 1535-1535. | 1.4 | 7 |
| 32 | Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. Blood Advances, 2021, , . | 5.2 | 5 |
| 33 | Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biology of Blood and Marrow Transplantation, 2020, 26, 1386-1393. | 2.0 | 5 |
| 34 | Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 830-830. | 1.4 | 3 |
| 35 | Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. Blood, 2020, 136, 2-3. | 1.4 | 3 |
| 36 | Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). Blood, 2020, 136, 37-38. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. Blood, 2020, 136, 40-41. | 1.4 | 2 |
| 38 | Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience. Blood, 2020, 136, 21-22. | 1.4 | 2 |
| 39 | Physical Therapy Assessment of Baseline Function and Endurance Predicts Short Term Outcomes in Commercial CAR T Patients with Lymphoma. Blood, 2021, 138, 570-570. | 1.4 | 1 |
| 40 | Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Research, 2018, 53, 223. | 1.3 | 0 |
| 41 | New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161. | 1.4 | 0 |
| 42 | Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. Blood, 2020, 136, 10-10. | 1.4 | 0 |